FK 778

Drug Profile

FK 778

Alternative Names: HMR 1715; MNA 715; X 920715

Latest Information Update: 05 Jul 2006

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Astellas Pharma
  • Class Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Liver transplant rejection; Multiple sclerosis; Renal transplant rejection; Transplant rejection

Most Recent Events

  • 30 Jun 2006 Discontinued - Preclinical for Autoimmune disorders in Germany (unspecified route)
  • 30 Jun 2006 Discontinued - Preclinical for Multiple sclerosis in Germany (unspecified route)
  • 30 Jun 2006 Discontinued - Phase-II for Liver transplant rejection in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top